Automatic monitoring of drug associated muscle adverse reaction in
102430 inpatients
Abstract
OBJECTIVE: To analyze clinical characteristics, incidence, and
distribution of drug associated muscle adverse reaction (DAMAR) in real
world inpatients, to provide references for clinical medication use.
METHODS: Automated retrospective monitored inpatients from 2022-5-1 to
2023-4-30 to obtain information about patients’ adverse reactions and
analyze. RESULTS: There were 1106 DAMARs among 102430 hospitalizations,
with an incidence of 1.08%, in which 125 cases of rhabdomyolysis with
an incidence of 0.12%. 75% of the patients experienced muscle adverse
reactions within 5 days after medication, and the median value of
elevated CK was 420.4 IU/L. There was no significant correlation between
duration of surgery and the elevation of CK, while the surgical
procedure had an effect. Age, male sex, obesity, hypertension, hepatic
and renal insufficiency, anemia, and other underlying diseases were risk
factors. The 114 drugs involved were mainly nervous system drugs,
antiinfectives for systemic use and cardiovascular system drugs, with
levofloxacin, pregabalin and parecoxib being the drugs with the highest
number of cases. CONCLUSION: Attention should be paid to patients with
the above risk factors. Monitor creatine kinase and related indexes when
using myotoxic drugs, to avoid the occurrence of serious adverse
reactions, which may affect the patients’ quality of life.